Industry sponsor intelligence

Kwang Dong Pharmaceutical co., ltd.Clinical Pipeline.

Lead-sponsor view of Kwang Dong Pharmaceutical co., ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.

Total: 1
Recruiting: 0
Active: 0
Completed: 1
Results posted: 0
Avg enrollment: 193

Pipeline overview

Programs by phase and activity.

Velocity

Kwang Dong Pharmaceutical co., ltd. trials by start year

Study start year · indexed snapshot

Development

Trials by phase

1phase labels

Early Phase 10

Phase 10

Phase 20

Phase 31

Phase 40

Product	Studies	Early / I	Phase II	Phase III	Phase IV	Active
Bremelanotide / PT-141 →	1	0	0	1	0	0

Active peptide trials

In motion now.

No studies in this snapshot.

Completed trials

Finished registry records.

NCT IDStudyPhase / statusEnrollmentUpdated

NCT04943068

A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Kwang Dong Pharmaceutical co., ltd. · Hypoactive Sexual Desire Disorder

Phase 3

Completed

193

2024-11

Search sponsor records

All Kwang Dong Pharmaceutical co., ltd. studies.

This page groups studies where Kwang Dong Pharmaceutical co., ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.

1 matching study

Last registry update first

NCT04943068Phase 3

A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Bremelanotide / PT-141Kwang Dong Pharmaceutical co., ltd.Hypoactive Sexual Desire Disorder

Completed

Enrollment: 193
Started: May 2021
Completion: May 2023
Locations: 1
Countries: 1
Updated: Nov 2024

End of 1 results

Recent updates

Latest registry movement.

NCT04943068A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)Nov 13, 2024